Kathleen Fuller

Access DB# 48063

SEARCH REQUEST FORM

1159

Scientific and Technical Information Center

Requester's Full Name: Rebecca Cook Examiner # : _____ Date: 8/1/01

Art Unit: 1614 Phone Number 308 4724 Serial Number: 09/879,688

Mail Box and Bldg/Room Location: CM 1 Results Format Preferred (circle): PAPER DISK E-MAIL

2D07 2B07

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): Joseph Steiner

_____

Earliest Priority Filing Date: _____

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Please search compounds of following claims

1, if possible

21

24 =

29

32 and use to treat alopecia

II Please provide structures of compounds of claim 28

Thanks

Rebecca

****

STAFF USE ONLY

Searcher: K. Fuller

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 8/15/01

Searcher Prep & Review Time: 25

Clerical Prep Time: _____

Online Time: 60

PTO-1590 (1-2000) Batch search

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) 4

Bibliographic _____

Litigation _____

Fulltext _____

Patent Family _____

Other _____

Vendors and cost where applicable

STN ✓

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

WWW/Internet _____

Other (specify) _____

=> FILE REG

FILE 'REGISTRY' ENTERED AT 11:02:04 ON 15 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 14 AUG 2001 HIGHEST RN 351405-63-5
DICTIONARY FILE UPDATES: 14 AUG 2001 HIGHEST RN 351405-63-5

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 11:02:10 ON 15 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 15 Aug 2001 VOL 135 ISS 8
FILE LAST UPDATED: 14 Aug 2001 (20010814/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> D QUE

L50 SCR 227
L52 SCR 1838
L54 SCR 1992
L56 STR



Covers claims 21, 24, 28, 29 and 32 (where V = N, will not run when V = CH or N)



3,728 structures

VAR G1=AK/CY
VAR G2=CH2/8
VAR G3=O/S/CH2
VAR G4=O/S
VAR G5=O/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY HIQ AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L59 SCR 1607
L61 3728 SEA FILE=REGISTRY SSS FUL L56 AND L50 AND L52 AND L54 AND L59
L64 1067 SEA FILE=HCAPLUS ABB=ON L61
L65 6 SEA FILE=HCAPLUS ABB=ON L64 AND (ALOPEC? OR ANTIALOPE?)
L66 1 SEA FILE=HCAPLUS ABB=ON L64 AND HAIR(4A)LOSS
L67 6 SEA FILE=HCAPLUS ABB=ON L65 OR L66

=> D L67 ALL 1-6 HITSTR

L67 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:209809 HCAPLUS
DN 132:237375
TI Preparation of bridged heterocyclic derivatives for treatment of neurological and other disorders
IN Li, Jia He; Limburg, David; Hamilton, Gregory S.; Steiner, Joseph P.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 503 pp.
CODEN: PIXXD2
DT Patent
LA English
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 27
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000016603	A2	20000330	WO 1998-US25577	19981203

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9919028 A1 20000410 AU 1999-19028 19981203
PRAI US 1998-101077 P 19980918
US 1998-159105 A 19980923
WO 1998-US25577 W 19981203
OS MARPAT 132:237375
GI



I

AB Heterocyclic compds. I [A and B taken together form a satd., unsatd., or arom. heterocyclic or carbocyclic bridged ring moiety which contains one or more O, CR12, S, SO, SO2, N, NH or imino; V = CH, S, or N; X = O, CH2, or S; m = 0 or 1; G is an acyl, sulfonyl, or alkyl moiety; R1 = H, (un)substituted alkyl, cycloalkyl, a carboxylic acid, a bridged ring moiety, etc.; Z = CH2, alkyl, O, S, a direct bond, NH or imino, etc.] or their pharmaceutically acceptable salts, esters, or solvates were prepd. for the treatment of neurol. and vision disorders, **alopecia**, etc. Thus, (2S)-(1-oxo-5-phenylpentyl)-1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine was prepd. from 1-chloro-4-phenylbutane, N-benzyl-L-proline Et ester, Me oxalyl chloride, and 1,1-dimethylpropylmagnesium chloride and shown to inhibit peptidyl prolyl isomerase with Ki = 31 nM.

ST pyrrolidine acyl prepn neurol vision disorder; neurol disorder bridged heterocycle; vision disorder bridged heterocycle; pipecolate diphenylpentylthio prepn neurol vision disorder

IT Proteins, specific or class
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(FKBP-12 (FK 506-binding protein, 12,000-mol.-wt.); prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Nervous system
(amyotrophic lateral sclerosis; prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Nervous system
(disease; prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Hair preparations
(growth stimulants; prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT **Alopecia**
Alzheimer's disease
Eye, disease
Immunosuppressants
Parkinson's disease
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Amino acids, preparation
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Heterocyclic compounds

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Immunophilins
RL: MSC (Miscellaneous)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT Eye, disease
(retina, ischemia; prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT 222171-83-7P 222171-84-8P 222171-85-9P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT 73096-19-2P 141084-63-1P 152754-34-2P 152754-35-3P 152754-36-4P
152754-38-6P 152754-42-2P 155668-51-2P 155668-53-4P 155668-86-3P
157757-22-7P 186268-50-8P 186268-51-9P 186268-52-0P 186268-53-1P
186268-54-2P 186268-56-4P 186268-57-5P 186268-58-6P 186268-63-3P
186268-64-4P 186268-65-5P 186268-66-6P 186268-67-7P 186268-68-8P
186452-05-1P 186452-06-2P 186452-07-3P 186452-08-4P 186452-09-5P
186452-10-8P 186452-11-9P 186452-12-0P 186452-13-1P 186452-14-2P
186452-15-3P 186452-16-4P 186452-17-5P 186452-18-6P 186452-19-7P
186452-20-0P 186834-62-8P 186834-66-2P 186834-69-5P 186834-70-8P
186834-71-9P 186834-74-2P 186834-75-3P 186834-76-4P 186834-77-5P
186834-78-6P 186834-79-7P 186834-80-0P 186834-81-1P 186834-82-2P
186834-83-3P 186834-84-4P 186834-85-5P 186834-86-6P 186834-87-7P
186834-88-8P 205388-13-2P 205388-14-3P 205388-15-4P 205388-16-5P
205388-17-6P 205388-20-1P 205388-22-3P 205388-23-4P 205388-24-5P
205388-25-6P 205388-26-7P 205388-27-8P 205388-28-9P 205388-29-0P
205388-30-3P 205388-31-4P 205388-32-5P 205388-33-6P 205388-35-8P
205388-36-9P 205388-37-0P 205388-38-1P 205388-39-2P 205388-41-6P
205388-42-7P 205388-43-8P 205388-44-9P 205388-47-2P 205388-48-3P
205388-49-4P 205388-50-7P 205388-51-8P 205388-53-0P 205388-54-1P
205388-55-2P 205388-57-4P 205388-58-5P 205388-59-6P 205388-61-0P
205388-62-1P 205388-63-2P 205388-80-3P 210048-11-6P 210048-13-8P
210048-17-2P 210048-19-4P 210048-20-7P 210048-21-8P 210048-22-9P
210103-54-1P 210103-55-2P 210103-56-3P 210103-57-4P 210103-58-5P
210103-59-6P 210103-60-9P 210103-61-0P 210103-62-1P 210103-63-2P
212762-79-3P 217178-10-4P 217180-44-4P 217180-57-9P 217180-59-1P
217180-90-0P 217186-52-2P 217186-53-3P 217186-54-4P 217186-55-5P
217186-56-6P 217186-57-7P 222171-24-6P 222171-25-7P 222171-27-9P
222171-28-0P 222171-29-1P 222171-30-4P 222171-31-5P 222171-32-6P
222171-82-6P 250636-40-9P 251916-50-4P 251948-45-5P 251948-46-6P
251953-27-2P **251953-29-4P** 251954-82-2P 252720-21-1P
261928-53-4P 261928-54-5P 261928-55-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT 152754-55-7 210048-30-9 210103-88-1 210103-92-7 212607-81-3
222171-48-4 222171-57-5 222171-58-6 251950-42-2 251969-48-9
252770-38-0 252770-39-1 258871-54-4
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT 95076-93-0, Peptidyl prolyl isomerase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and

other disorders)

IT 62-56-6, Thiourea, reactions 86-81-7, 3,4,5-Trimethoxybenzaldehyde 96-15-1, 2-Methylbutylamine 103-63-9, Phenethyl bromide 108-98-5, Phenyl mercaptan, reactions 122-97-4, 3-Phenyl-1-propanol 955-40-8, n-Benzyl-L-proline ethyl ester 1122-82-3, Cyclohexyl isothiocyanate 2133-40-6, L-Proline methyl ester hydrochloride 2605-67-6, Methyl (triphenylphosphoranylidene)acetate 2859-67-8, 3-(3-Pyridyl)-1-propanol 3173-53-3, Cyclohexyl isocyanate 4830-93-7, 1-Chloro-4-phenylbutane 5406-18-8, 3-(p-Methoxyphenyl)-1-propanol 5781-53-3, Methyl oxalyl chloride 7531-52-4, L-Prolinamide 15761-39-4 23356-96-9, s + 2-Pyrrolidinemethanol 26250-84-0 28276-08-6, 1,1-Dimethylpropylmagnesium chloride 32559-18-5, Methyl pipecolate hydrochloride 34592-47-7, L-Thioproline 222171-36-0
RL: RCT (Reactant)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT 104-53-0P, Benzenepropanal 17486-86-1P 20329-96-8P 57293-19-3P 69603-49-2P, 3-Pyridinepropanethiol 88537-44-4P 89113-44-0P 139419-63-9P 186268-77-9P 186268-78-0P 205388-66-5P 205388-67-6P 205388-68-7P 210048-37-6P 210048-38-7P 210103-98-3P 210103-99-4P 217186-09-9P 217186-59-9P 217186-60-2P 217186-61-3P **222171-37-1P** 222171-38-2P 251917-76-7P 251953-31-8P 251953-33-0P 251954-80-0P 261928-56-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT 30273-62-2P 53560-26-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

IT **251953-27-2P 251953-29-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)

RN 251953-27-2 HCAPLUS
CN 4-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-phenylpropyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28

RN 251953-29-4 HCAPLUS
CN 4-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28

IT **252770-38-0**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)
RN 252770-38-0 HCAPLUS
CN 2-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28

IT **222171-37-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of bridged heterocyclic derivs. for treatment of neurol. and other disorders)
RN 222171-37-1 HCAPLUS
CN 4-Oxazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, methyl ester (9CI) (CA INDEX NAME)



L67 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:808660 HCAPLUS
DN 132:44998
TI N-linked sulfonamides of heterocyclic thioesters, their preparation, and their use in treating **alopecia** and promoting hair growth
IN Steiner, Joseph P.; Hamilton, Gregory S.
PA GPI Nil Holdings, Inc., USA
SO U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 869,426.

CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-40
ICS A61K031-445
NCL 514424000
CC 1-12 (Pharmacology)
Section cross-reference(s): 27, 63
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004993	A	19991221	US 1998-89375	19980603
	US 5945441	A	19990831	US 1997-869426	19970604
	ZA 9804621	A	19981204	ZA 1998-4621	19980529
	ZA 9804778	A	19981204	ZA 1998-4778	19980603
	ZA 9804783	A	19981204	ZA 1998-4783	19980603
	US 6239164	B1	20010529	US 1999-369860	19990809
PRAI	US 1997-869426	A2	19970604		

OS MARPAT 132:44998
AB Pharmaceutical compns. and methods for treating **alopecia** and promoting hair growth are provided which use N-linked sulfonamides of heterocyclic thioesters (prepn. described).
ST sulfonamide heterocyclic thioester prepn **alopecia** pharmaceutical; hair growth sulfonamide heterocyclic thioester prepn
IT Proteins, specific or class
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(FKBP (FK 506-binding protein), FKBP-type immunophilin; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Proteins, specific or class
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(FKBP-12 (FK 506-binding protein, 12,000-mol.-wt.); N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Immunophilins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(FKBP-type; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT **Alopecia**
Shampoos
(N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Sulfonamides
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Drug delivery systems
(emulsions; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Hair preparations
(growth stimulants; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Drug delivery systems
(liqs.; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Drug delivery systems
(lotions; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
IT Drug delivery systems
(ointments, creams; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)

IT Esters, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thio; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)

IT 210048-11-6P 210048-13-8P 210048-25-2P 222171-28-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)

IT 186452-09-5, GPI 1046 205388-16-5, GPI 1389 205388-30-3, GPI 1234
210048-11-6D, esters 210048-17-2 210048-19-4 210048-20-7
210048-21-8 210048-22-9 210048-25-2D, esters 210048-30-9, GPI 1312
210048-30-9D, esters 210103-88-1, GPI 1605 222171-24-6 222171-25-7
222171-27-9 222171-28-0D, esters 222171-29-1 222171-30-4
222171-31-5 222171-32-6 252720-21-1 **252770-38-0**, GPI 1572
252770-39-1, GPI 1511
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)

IT 104-53-0P, 3-Phenyl-1-propanal 17486-86-1P, 1,5-Diphenyl-3-pentanol
57293-19-3P 88537-44-4P 210048-37-6P 210048-38-7P 217186-63-5P
251917-77-8P 252720-22-2P 252720-23-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)

IT 62-56-6, Thiourea, reactions 98-09-9, Benzenesulfonyl chloride
98-59-9, p-Toluenesulfonyl chloride 103-63-9, 2-(Bromoethyl)benzene
122-97-4, 3-Phenyl-1-propanol 1939-99-7, .alpha.-Toluenesulfonyl chloride 5406-18-8, 3-(p-Methoxyphenyl)-1-propanol 15761-39-4
26250-84-0
RL: RCT (Reactant)
(reaction; N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)

RE.CNT 86

RE

(1) Anon; DE 2505114 1976 HCAPLUS
(2) Anon; EP 12401 1980 HCAPLUS
(3) Anon; EP 48159 1982 HCAPLUS
(4) Anon; EP 50800 1982 HCAPLUS
(5) Anon; EP 73143 1983 HCAPLUS
(6) Anon; EP 88350 1983 HCAPLUS
(7) Anon; ZA 9207782 1983 HCAPLUS
(8) Anon; EP 196841 1986 HCAPLUS
(9) Anon; DE 3508251 1986 HCAPLUS
(10) Anon; EP 260118 1988 HCAPLUS
(11) Anon; WO 8800040 1988 HCAPLUS
(12) Anon; WO 8809789 1988 HCAPLUS
(13) Anon; EP 333174 1989 HCAPLUS
(14) Anon; WO 8906234 1989 HCAPLUS
(15) Anon; EP 0420707 1990 HCAPLUS
(16) Anon; EP 0471135 1990 HCAPLUS
(17) Anon; EP 352000 1990 HCAPLUS
(18) Anon; EP 378318 1990 HCAPLUS
(19) Anon; DE 3931051 1990 HCAPLUS
(20) Anon; WO 9012805 1990 HCAPLUS
(21) Anon; EP 0443983 1991 HCAPLUS
(22) Anon; EP 0494005 1991 HCAPLUS
(23) Anon; DE 4015255 1991 HCAPLUS
(24) Anon; EP 405994 1991 HCAPLUS
(25) Anon; EP 419049 1991 HCAPLUS

(26) Anon; EP 423714 1991 HCAPLUS
(27) Anon; WO 9104985 1991 HCAPLUS
(28) Anon; WO 9113088 1991 HCAPLUS
(29) Anon; JP 04-149166 1992 HCAPLUS
(30) Anon; EP 0519819 1992 HCAPLUS
(31) Anon; GB 2247456 1992 HCAPLUS
(32) Anon; EP 468339 1992 HCAPLUS
(33) Anon; WO 9200278 1992 HCAPLUS
(34) Anon; WO 9203472 1992 HCAPLUS
(35) Anon; WO 9204370 1992 HCAPLUS
(36) Anon; JP 05-178824 1993 HCAPLUS
(37) Anon; EP 564924 1993 HCAPLUS
(38) Anon; EP 572365 1993 HCAPLUS
(39) Anon; EP 652229 1995 HCAPLUS
(40) Anon; EP 0823419 1997 HCAPLUS
(41) Armistead; US 5192773 1993 HCAPLUS
(42) Armistead; US 5330993 1994 HCAPLUS
(43) Armistead; US 5516797 1996 HCAPLUS
(44) Armistead; US 5620971 1997 HCAPLUS
(45) Birkenshaw, T; Bioorganic & Medicinal Chemistry Letters 1994, V4(21), P2501
(46) Burbaum; US 5319098 1994 HCAPLUS
(47) Burbaum; US 5424454 1995 HCAPLUS
(48) Caffrey, M; Bioorganic & Medicinal Chemistry Letters 1994, V4(21), P2507 HCAPLUS
(49) Connell; US 5385918 1995 HCAPLUS
(50) Davis; US 5292747 1994 HCAPLUS
(51) Eberle; US 5284826 1994 HCAPLUS
(52) Gavras; US 4574079 1986 HCAPLUS
(53) Gold; US 4808573 1989 HCAPLUS
(54) Gold; US 4818749 1989 HCAPLUS
(55) Goulet; US 5147877 1992 HCAPLUS
(56) Goulet; US 5189042 1993 HCAPLUS
(57) Goulet; US 5258389 1993 HCAPLUS
(58) Goulet; US 5532248 1996 HCAPLUS
(59) Hackl; US 5414083 1995 HCAPLUS
(60) Hamilton; US 5614547 1997 HCAPLUS
(61) Harris; US 4374829 1983 HCAPLUS
(62) Hauer; US 5342625 1994 HCAPLUS
(63) Hauske, J; J of Medicinal Chemistry 1992, V35, P4284 HCAPLUS
(64) Hewitt; US 4996193 1991 HCAPLUS
(65) Krapcho; US 4310461 1982 HCAPLUS
(66) Krapcho; US 4390695 1983 HCAPLUS
(67) Krapcho; US 4578474 1986 HCAPLUS
(68) Luly; US 5457111 1995 HCAPLUS
(69) Michnick; US 5470878 1995 HCAPLUS
(70) Nelson; US 5385908 1995 HCAPLUS
(71) Norton; US 5506228 1996 HCAPLUS
(72) Ok; US 5208241 1993 HCAPLUS
(73) Organ; US 5284877 1994 HCAPLUS
(74) Proctor; US 5472687 1995 HCAPLUS
(75) Proctor; US 5714510 1998 HCAPLUS
(76) Rinehart; US 5294603 1994 HCAPLUS
(77) Rupprecht; US 5284840 1994 HCAPLUS
(78) Schreiber; US 5447915 1995 HCAPLUS
(79) Shanklin; US 4593102 1986 HCAPLUS
(80) Sharpe; US 5631017 1997
(81) Sharpe; US 5703088 1997 HCAPLUS
(82) Shimano; US 4531964 1985 HCAPLUS
(83) Skotnicki; US 5252579 1993 HCAPLUS
(84) Takeuchi; US 5359138 1994 HCAPLUS
(85) Winkley; US 4438031 1984 HCAPLUS
(86) Zelle; US 5543423 1996 HCAPLUS
IT **252770-38-0**, GPI 1572

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-linked sulfonamides of heterocyclic thioesters, prepn., and use in treating **alopecia** and promoting hair growth)
RN 252770-38-0 HCAPLUS
CN 2-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28

L67 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:784085 HCAPLUS
DN 132:18814
TI Aza-heterocyclic compounds used to treat neurological disorders and **hair loss**
IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Li, Jia-He; Steiner, Joseph P.
PA Guilford Pharmaceuticals Inc., USA; Amgen, Inc.
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D263-06
ICS A61K031-42; C07D277-06; A61K031-425; C07D207-16; A61K031-40; C07D211-60; A61K031-445
CC 1-12 (Pharmacology)
Section cross-reference(s): 28, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962888	A1	19991209	WO 1998-US25574	19981203
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9917082	A1	19991220	AU 1999-17082	19981203
	BR 9815919	A	20010220	BR 1998-15919	19981203
	EP 1102756	A1	20010530	EP 1998-961867	19981203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2000006117	A	20010201	NO 2000-6117	20001201
PRAI	US 1998-87843	P	19980603		
	WO 1998-US25574	W	19981203		

OS MARPAT 132:18814
GI



I

AB The invention is directed to carboxylic acids and isosteres of heterocyclic ring compds. I [X, Y, Z = C, O, S, N (provided that not all X, Y, Z are C); n = 1-3; A = R1C(O)C(O), R1C(O)C(S), R1SO2, (E)(R1)NC(O); R1, E = H, C1-9 (un)branched alkyl or alkenyl, aryl, etc.; D = C1-10 (un)branched alkyl, ethylene, butylene; R2 = carboxylic acid or carboxylic acid isostere] which have multiple heteroatoms within the heterocyclic ring, derivs. contg. N-linked diketos, sulfonamides, ureas and carbamates attached thereto, their prepn. and use for treating neurol. disorders including phys. damaged nerves and neurodegenerative diseases, as well as for treating **alopecia** and promoting hair growth.

ST azaheterocyclic deriv prepn neurol disorder **alopecia**; heterocyclic deriv neurol disorder **alopecia**; hair growth aza heterocyclic deriv; nerve damage aza heterocyclic deriv; neurodegenerative disease aza heterocyclic deriv

IT Nervous system
(amyotrophic lateral sclerosis; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Neurotrophic factors
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain-derived; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Nervous system
(degeneration; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Nervous system
(disease; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Drug delivery systems
(emulsions; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Neurotrophic factors
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glial-derived; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Hair preparations
(growth stimulants; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT **Alopecia**
Anti-Alzheimer's agents
Antiparkinsonian agents
Drug delivery systems
Nervous system agents
Shampoos
(heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT Ciliary neurotrophic factor
Neurotrophic factors
Platelet-derived growth factors
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic compds. for treatment of neurol. disorder or **hair**

loss)
IT Brain, disease
Spinal cord
(injury; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Drug delivery systems
(liqs.; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Drug delivery systems
(lotions; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Regeneration, animal
(nerve; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Drug delivery systems
(ointments, creams; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Nerve, disease
(peripheral neuropathy; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Nerve, disease
(peripheral, injury; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Nerve
(regeneration; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT Brain, disease
(stroke, brain damage-assocd.; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT 251952-75-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
IT 61912-98-9, Insulin-like growth factor 61912-98-9D, Insulin-like growth factor, truncated derivs. 100391-96-6 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 130939-66-1, Neurotropin 3 143375-33-1, Neurotropin 4 148499-03-0, Neurotropin 5
205388-68-7 251917-34-7 251917-35-8 251917-36-9 251917-37-0
251917-38-1 251917-39-2 251917-40-5 251917-41-6 251917-42-7
251951-42-5 251951-43-6 251951-44-7 251951-45-8 251951-46-9
251951-47-0 251951-48-1 251951-49-2 251951-50-5 251951-51-6
251951-52-7 251951-53-8 251951-54-9 251951-55-0 251951-56-1
251951-57-2 251951-58-3 251951-59-4 251951-60-7 251951-61-8
251951-62-9 251951-63-0 251951-64-1 251951-65-2 251951-66-3
251951-67-4 251951-68-5 251951-69-6 251951-70-9 251951-71-0
251951-72-1 251951-73-2 251951-74-3 251951-75-4 251951-76-5
251951-77-6 251951-78-7 251951-79-8 251951-80-1 251951-81-2
251951-82-3 251951-83-4 251951-84-5 251951-85-6 251951-86-7
251951-87-8 251951-88-9 251951-89-0 251951-90-3 251951-91-4
251951-92-5 251951-93-6 251951-94-7 251951-95-8 251951-96-9
251951-97-0 251951-98-1 251951-99-2 251952-00-8 251952-01-9
251952-02-0 251952-03-1 251952-04-2 251952-05-3 251952-06-4
251952-07-5 251952-08-6 251952-09-7 251952-10-0 251952-11-1
251952-12-2 251952-14-4 251952-15-5 251952-16-6 251952-17-7
251952-18-8 251952-19-9 251952-20-2 251952-21-3 251952-22-4
251952-23-5 251952-24-6 251952-25-7 251952-26-8 251952-27-9
251952-28-0 251952-29-1 251952-30-4 251952-31-5 251952-32-6
251952-33-7 251952-34-8 251952-35-9 251952-36-0 251952-37-1
251952-38-2 251952-39-3 251952-40-6 251952-41-7 251952-42-8
251952-43-9 251952-44-0 251952-45-1 251952-46-2 251952-47-3
251952-48-4 251952-49-5 251952-50-8 251952-51-9 251952-52-0
251952-53-1 251952-54-2 251952-55-3 251952-56-4 251952-57-5

251952-58-6 251952-60-0 **251952-61-1** 251952-62-2
251952-63-3 251952-64-4 251952-65-5 251952-66-6 251952-67-7
251952-68-8 251952-69-9 251952-70-2 251952-71-3 251952-72-4
251952-73-5 251952-74-6 251952-76-8 251952-77-9 251952-78-0
251952-79-1 251952-80-4 251952-81-5 251952-82-6 251952-83-7
251952-84-8 251952-85-9 251952-86-0 251952-87-1 251952-88-2
251952-89-3 251952-90-6 251952-91-7 251952-92-8 251952-93-9
251952-94-0 251952-95-1 251952-96-2 251952-97-3 251952-98-4
251952-99-5 251953-00-1 251953-01-2 251953-02-3 251953-03-4
251953-04-5 251953-05-6 251953-06-7 251953-07-8 251953-09-0
251953-10-3 251953-11-4 251953-12-5 251953-13-6 251953-14-7
251953-15-8 251953-16-9 251953-17-0 251953-18-1 251953-19-2
251953-20-5 251953-21-6 251953-22-7 251953-23-8 251953-24-9
251953-25-0 251953-26-1 251953-28-3 251953-30-7 251953-32-9
251953-34-1 251953-35-2 251953-36-3 251953-37-4 251953-38-5
251953-39-6 251953-40-9 251953-41-0 251953-42-1 251953-43-2
251953-44-3 251953-45-4 251953-46-5 251953-47-6 251953-48-7
251953-49-8 251953-50-1 251953-51-2 251953-52-3 251953-53-4
251953-54-5 251953-55-6 251953-56-7 251953-57-8 251953-58-9
251953-59-0 251953-60-3 251953-61-4 251953-62-5 251953-63-6
251953-64-7 251953-65-8 251953-66-9 251953-67-0 251953-68-1
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT 251953-69-2 251953-70-5 251953-71-6 251953-72-7 251953-73-8
251953-74-9 251953-75-0 251953-76-1 251953-77-2 251953-78-3
251953-79-4 251953-80-7 251953-81-8 251953-82-9 251953-83-0
251953-84-1 251953-85-2 251953-86-3 251953-87-4 251953-88-5
251953-89-6 251953-90-9 251953-91-0 251953-92-1 251953-93-2
251953-94-3 251953-95-4 251953-96-5 251953-97-6 251953-98-7
251953-99-8 251954-00-4 251954-01-5 251954-02-6 251954-03-7
251954-05-9 251954-07-1 251954-08-2 251954-09-3 251954-10-6
251954-11-7 251954-12-8 251954-13-9 251954-14-0 251954-15-1
251954-16-2 251954-17-3 251954-18-4 251954-19-5 251954-20-8
251954-21-9 251954-22-0 251954-23-1 251954-24-2 251954-25-3
251954-26-4 251954-27-5 251954-28-6 251954-29-7 251954-30-0
251954-31-1 251954-32-2 251954-33-3 251954-34-4
251954-35-5 251954-36-6 251954-37-7 251954-38-8 251954-39-9
251954-40-2 251954-41-3 251954-42-4 251954-43-5 251954-44-6
251954-45-7 251954-46-8 251954-47-9 251954-48-0 251954-49-1
251954-50-4 251954-51-5 251954-52-6 251954-53-7 251954-54-8
251954-55-9 251954-56-0 251954-57-1 251954-58-2 251954-59-3
251954-60-6 251954-61-7 251954-62-8 251954-63-9 251954-64-0
251954-65-1 251954-66-2 251954-67-3 251954-68-4 251954-69-5
251954-70-8 251954-71-9 251954-72-0 251954-73-1 251954-74-2
251954-75-3 251954-78-6 251954-79-7 251954-83-3 251954-84-4
251954-85-5 251954-86-6 251955-57-4
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT 251954-80-0P 251954-81-1P 251954-82-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

IT 5781-53-3, Methyl oxalyl chloride 28276-08-6 222171-36-0
RL: RCT (Reactant)
(reaction; heterocyclic compds. for treatment of neurol. disorder or **hair loss**)

RE.CNT 6
RE
(1) Guilford Pharm Inc; WO 9640633 A 1996 HCAPLUS
(2) Guilford Pharm Inc; WO 9855090 A 1998 HCAPLUS

(3) Mitsubishi Chem Ind; EP 0006633 A 1980 HCAPLUS
(4) Mitsubishi Chem Ind Ltd; JP 56061390 A 1981
(5) Ono Pharmaceutical Co; EP 0769498 A 1997 HCAPLUS
(6) Vertex Pharma; WO 9200278 A 1992 HCAPLUS
IT **251952-61-1 251954-31-1**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic compds. for treatment of neurol. disorder or **hair loss**)
RN 251952-61-1 HCAPLUS
CN 2H-1,3-Oxazine-4-carboxamide, N-cyano-N-ethyltetrahydro-3-[2-(4-methylphenyl)-2-oxo-1-thioxoethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251954-31-1 HCAPLUS
CN 2H-1,3-Oxazine-2-carboxamide, N-cyano-N-ethyltetrahydro-3-[2-(4-methylphenyl)-2-oxo-1-thioxoethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L67 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:783907 HCAPLUS
DN 132:26636
TI Heterocyclic ester and amides for hair growth compositions
IN Hamilton, Gregory S.; Steiner, Joseph P.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K031-425; A61K031-44; A61K031-415; A61K031-54; A61K031-535; A61K031-495
CC 62-3 (Essential Oils and Cosmetics)
Section cross-reference(s): 28
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 9962487 A1 19991209 WO 1998-US11250 19980603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9877170 A1 19991220 AU 1998-77170 19980603
EP 1085853 A1 20010328 EP 1998-925156 19980603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRAI WO 1998-US11250 A 19980603
OS MARPAT 132:26636
AB This invention relates to pharmaceutical compns. and methods for treating **alopecia** and promoting hair growth using heterocyclic esters or amides. Thus, 3-phenyl-1-propyl(2S)-1-(3,3-dimedimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate (I) was obtained by the reaction of L-thioproline with Me oxalyl chloride followed by the reaction with 3-phenyl-1-propanol and subsequently with 1,1-dimethpropylmagnesium chloride. Thus, a lotion contained 95% EtOH 80.0, I 0.005, hinokitol 0.01, ethoxylated hardened castor oil 0.5, and water 19.0%, and perfume and dye qs.
ST ester heterocyclic hair growth prepn; amide heterocyclic hair growth prepn
IT Hair preparations
(creams; heterocyclic ester and amides for hair growth compns.)
IT Hair preparations
(emulsions; heterocyclic ester and amides for hair growth compns.)
IT Hair preparations
(growth stimulants; heterocyclic ester and amides for hair growth compns.)
IT **Alopecia**
Shampoos
(heterocyclic ester and amides for hair growth compns.)
IT Amides, biological studies
Esters, biological studies
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic; heterocyclic ester and amides for hair growth compns.)
IT Hair preparations
(lotions; heterocyclic ester and amides for hair growth compns.)
IT **251953-27-2P 251953-29-4P**
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic ester and amides for hair growth compns.)
IT 122-97-4, 3-Phenyl-1-propanol 2859-67-8, 3-Pyridinepropanol 5781-53-3, Methyl oxalyl chloride 28276-08-6 34592-47-7, L-Thioproline
RL: RCT (Reactant)
(heterocyclic ester and amides for hair growth compns.)
IT 251953-31-8P 251953-33-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(heterocyclic ester and amides for hair growth compns.)
RE.CNT 7
RE
(1) Farmitalia Carlo Erba; WO 9403476 A 1994 HCAPLUS
(2) Fujisawa Pharmaceutical Co Ltd; EP 0423714 A 1991 HCAPLUS
(3) Goulet, M; US 5147877 A 1992 HCAPLUS
(4) Guilford Pharmaceuticals Inc; WO 9813343 A 1998 HCAPLUS
(5) Hallam, K; EP 0471135 A 1992 HCAPLUS
(6) Merck & Co Inc; WO 9512398 A 1995 HCAPLUS
(7) Vertex Pharmaceuticals Inc; WO 9200278 A 1992 HCAPLUS

IT **251953-27-2P 251953-29-4P**
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic ester and amides for hair growth compns.)
RN 251953-27-2 HCAPLUS
CN 4-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-phenylpropyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28

RN 251953-29-4 HCAPLUS
CN 4-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28

L67 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:613942 HCAPLUS
DN 131:243593
TI Preparation of peptides as inhibitors of caspases
IN Wannamaker, Marion W.; Bemis, Guy W.; Charifson, Paul S.; Lauffer, David J.; Mullican, Michael D.; Murcko, Mark A.; Wilson, Keith P.; Janetka, James W.; Davies, Robert J.; Grillot, Anne-Laure; Shi, Zhan; Forster, Cornelia J.
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 297 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K005-023
ICS A61K038-04; A61K031-47; A61K038-03; C07D401-12
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 7
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947545	A2	19990923	WO 1999-US5919	19990319
	WO 9947545	A3	19991125		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU	9930986	A1	19991011	AU 1999-30986	19990319
BR	9909660	A	20001121	BR 1999-9660	19990319
EP	1064298	A2	20010103	EP 1999-912662	19990319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO	2000004546	A	20001109	NO 2000-4546	20000912
PRAI US	1998-78770	A1	19980319		
	WO 1999-US5919	W	19990319		

OS MARPAT 131:243593

AB Peptides R1NR2XCONR4CR52CONHY [Y = CH(CHO)CH2(CH2)mCOR7, (m = 0 or 1 and R7 = OH or ester, NHOH) or cyclic lactol deriv. when R7 is OH; X = CR32 or NR3 (R3 = H, an amino acid side chain, alkyl, cycloalkyl, aryl, etc.); R1 = H, R8, COR8, COCOR8, SO2R8, SOR8, CO2R8, CONHR8, SO2NHR8, SONHR8, COCONHR8, COCH:CHR8, etc. (R8 = alkyl, cycloalkyl, aryl, etc.); R2 = H or R2 and R3 may form a ring; R4 = H and R5 = H, amino acid side chain, R8, etc. or R4 and R5 may form a ring] were prepd. as inhibitors of caspases. Thus, p-AcNHC6H4CO-L-Val-L-Pro-NHCH(CHO)CH2CO2H-(S) was prepd. by the solid-phase method and showed ki < 10 nm for inhibition of interleukin-1.beta. converting enzyme (ICE, caspase-1).

ST peptide prepn inhibitor caspase

IT Hepatitis
(B; prepn. of peptides as inhibitors of caspases)

IT Hepatitis
(C; prepn. of peptides as inhibitors of caspases)

IT Intestine, disease
(Crohn's; prepn. of peptides as inhibitors of caspases)

IT Sarcoma
(Kaposi's; prepn. of peptides as inhibitors of caspases)

IT Leukemia
(acute myelogenous; prepn. of peptides as inhibitors of caspases)

IT Dermatitis
(atopic; prepn. of peptides as inhibitors of caspases)

IT Stomach, disease
(autoimmune gastritis; prepn. of peptides as inhibitors of caspases)

IT Anemia (disease)
(autoimmune hemolytic anemia; prepn. of peptides as inhibitors of caspases)

IT Thyroid gland, disease
(autoimmune thyroiditis; prepn. of peptides as inhibitors of caspases)

IT Leukemia
(chronic myelocytic; prepn. of peptides as inhibitors of caspases)

IT Disease, animal
(degenerative; prepn. of peptides as inhibitors of caspases)

IT Infection
(dengue; prepn. of peptides as inhibitors of caspases)

IT Kidney, disease
(glomerulonephritis; prepn. of peptides as inhibitors of caspases)

IT Transplant and Transplantation
(graft-vs.-host reaction; prepn. of peptides as inhibitors of caspases)

IT Intestine, disease
(inflammatory; prepn. of peptides as inhibitors of caspases)

IT Brain, disease
(injury; prepn. of peptides as inhibitors of caspases)

IT Diabetes mellitus
(insulin-dependent; prepn. of peptides as inhibitors of caspases)

IT Brain, disease

Heart, disease
(ischemia; prepn. of peptides as inhibitors of caspases)
IT Melanoma
(metastatic; prepn. of peptides as inhibitors of caspases)
IT Agranulocytosis
(neutropenia; prepn. of peptides as inhibitors of caspases)
IT Respiratory distress syndrome
(newborn; prepn. of peptides as inhibitors of caspases)
IT Pancreas, disease
(pancreatitis; prepn. of peptides as inhibitors of caspases)
IT Aging, animal
Alcoholism
Alopecia
Alzheimer's disease
Anti-inflammatory agents
Antiasthmatics
Antiviral agents
Apoptosis
Autoimmune disease
Bone, disease
Encephalitis
Graves' disease
Leukemia
Lupus erythematosus
Multiple myeloma
Multiple sclerosis
Myasthenia gravis
Myelodysplastic syndromes
Osteoarthritis
Osteoporosis
Parkinson's disease
Psoriasis
Rheumatoid arthritis
Sepsis
Spinal muscular atrophy
Transplant rejection
(prepn. of peptides as inhibitors of caspases)
IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of caspases)
IT Connective tissue
(scleroderma; prepn. of peptides as inhibitors of caspases)
IT Shock (circulatory collapse)
(septic; prepn. of peptides as inhibitors of caspases)
IT Brain, disease
(stroke; prepn. of peptides as inhibitors of caspases)
IT Platelet (blood)
(thrombocytopenia; prepn. of peptides as inhibitors of caspases)
IT Intestine, disease
(ulcerative colitis; prepn. of peptides as inhibitors of caspases)
IT Hepatitis
(viral, chronic active; prepn. of peptides as inhibitors of caspases)
IT Fever and Hyperthermia
(yellow; prepn. of peptides as inhibitors of caspases)
IT 244133-06-0P 244133-10-6P 244133-13-9P 244133-14-0P 244133-15-1P
244133-18-4P 244133-21-9P 244133-26-4P 244133-30-0P 244133-33-3P
244133-34-4P 244133-35-5P 244133-36-6P 244133-37-7P 244133-38-8P
244133-39-9P 244133-40-2P 244133-41-3P 244133-42-4P 244133-43-5P
244133-44-6P 244133-45-7P 244133-46-8P 244133-47-9P 244133-48-0P
244133-49-1P 244133-50-4P 244133-57-1P 244133-58-2P 244133-59-3P
244133-60-6P 244133-61-7P 244133-62-8P 244133-63-9P 244133-64-0P
244133-65-1P 244133-66-2P 244133-67-3P 244133-68-4P 244133-69-5P

244133-70-8P 244133-71-9P 244133-72-0P 244133-73-1P 244133-74-2P
244133-75-3P 244133-76-4P 244133-77-5P 244133-78-6P 244133-79-7P
244133-80-0P 244133-81-1P 244133-82-2P 244133-83-3P 244133-84-4P
244133-85-5P 244133-86-6P 244133-87-7P 244133-88-8P 244133-89-9P
244133-90-2P 244133-91-3P 244133-92-4P 244133-93-5P 244133-94-6P
244133-95-7P 244133-96-8P 244133-97-9P 244133-98-0P 244133-99-1P
244134-00-7P 244134-01-8P 244134-02-9P 244134-03-0P 244134-04-1P
244134-05-2P 244134-06-3P 244134-07-4P 244134-08-5P 244134-09-6P
244134-10-9P 244134-40-5P 244134-41-6P 244134-42-7P 244134-46-1P
244134-47-2P 244134-51-8P 244134-56-3P 244134-57-4P 244134-66-5P
244134-67-6P 244134-94-9P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of caspases)

IT 130275-78-4
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of peptides as inhibitors of caspases)

IT 244130-74-3P 244130-75-4P 244130-76-5P 244130-77-6P 244130-78-7P
244130-79-8P 244130-80-1P 244130-81-2P 244130-82-3P 244130-83-4P
244130-84-5P 244130-85-6P 244130-86-7P 244130-87-8P 244130-88-9P
244130-89-0P 244130-90-3P 244130-91-4P 244130-94-7P 244130-95-8P
244130-96-9P 244130-97-0P 244130-98-1P 244130-99-2P 244131-00-8P
244131-01-9P 244131-02-0P 244131-04-2P 244131-05-3P 244131-06-4P
244131-07-5P 244131-08-6P 244131-09-7P 244131-10-0P 244131-11-1P
244131-12-2P 244131-13-3P 244131-14-4P 244131-15-5P 244131-16-6P
244131-18-8P 244131-19-9P 244131-20-2P 244131-21-3P 244131-22-4P
244131-24-6P 244131-25-7P 244131-26-8P 244131-27-9P
244131-28-0P 244131-29-1P 244131-30-4P 244131-31-5P 244131-32-6P
244131-33-7P 244131-34-8P 244131-35-9P 244131-36-0P 244131-37-1P
244131-38-2P 244131-39-3P 244131-40-6P 244131-41-7P 244131-42-8P
244131-43-9P 244131-44-0P 244131-45-1P 244131-46-2P 244131-47-3P
244131-48-4P 244131-49-5P 244131-50-8P 244131-51-9P 244131-52-0P
244131-53-1P 244131-54-2P 244131-55-3P 244131-56-4P 244131-57-5P
244131-58-6P 244131-59-7P 244131-60-0P 244131-61-1P 244131-62-2P
244131-63-3P 244131-64-4P 244131-65-5P 244131-66-6P 244131-67-7P
244131-68-8P 244131-69-9P 244131-70-2P 244131-71-3P 244131-72-4P
244131-73-5P 244131-74-6P 244131-75-7P 244131-76-8P 244131-77-9P
244131-78-0P 244131-79-1P 244131-80-4P 244131-81-5P 244131-82-6P
244131-83-7P 244131-84-8P 244131-85-9P 244131-86-0P 244131-87-1P
244131-88-2P 244131-89-3P 244131-90-6P 244131-91-7P 244131-92-8P
244131-93-9P 244131-94-0P 244131-95-1P 244131-96-2P 244131-97-3P
244131-98-4P 244131-99-5P 244132-00-1P 244132-01-2P 244132-02-3P
244132-03-4P 244132-04-5P 244132-05-6P 244132-06-7P 244132-07-8P
244132-08-9P 244132-09-0P 244132-10-3P 244132-11-4P 244132-12-5P
244132-13-6P 244132-14-7P 244132-15-8P 244132-16-9P 244132-17-0P
244132-18-1P 244132-19-2P 244132-20-5P 244132-21-6P 244132-22-7P
244132-23-8P 244132-24-9P 244132-25-0P 244132-26-1P 244132-32-9P
244132-33-0P 244132-34-1P 244132-35-2P 244132-36-3P 244132-37-4P
244132-38-5P 244132-39-6P 244132-40-9P 244132-41-0P 244132-42-1P
244132-43-2P 244132-44-3P 244132-45-4P 244132-46-5P 244132-47-6P
244132-48-7P 244132-49-8P 244132-50-1P 244132-51-2P 244132-52-3P
244132-53-4P 244132-54-5P 244132-55-6P 244132-56-7P 244132-57-8P
244132-58-9P 244132-59-0P 244132-60-3P 244132-61-4P 244132-62-5P
244132-63-6P 244132-64-7P 244132-65-8P 244132-66-9P 244132-67-0P
244132-68-1P 244132-69-2P 244132-70-5P 244132-71-6P 244132-72-7P
244132-73-8P 244132-74-9P 244132-75-0P 244132-76-1P 244132-77-2P
244132-78-3P 244132-79-4P 244132-80-7P 244132-81-8P 244132-82-9P
244132-83-0P 244132-84-1P 244132-85-2P 244132-86-3P 244132-87-4P
244132-88-5P 244132-89-6P 244132-90-9P 244132-91-0P 244132-92-1P
244132-93-2P 244132-94-3P 244132-95-4P 244132-96-5P 244132-97-6P
244132-98-7P 244132-99-8P 244133-00-4P 244133-01-5P 244133-02-6P
244133-07-1P 244133-11-7P 244133-16-2P 244133-19-5P 244133-22-0P

244133-27-5P 244133-31-1P 244134-48-3P 244134-49-4P 244134-52-9P
244134-55-2P 244134-58-5P 244134-59-6P 244134-60-9P 244134-61-0P
244134-62-1P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of caspases)

IT 244134-68-7P 244134-69-8P 244134-70-1P 244134-71-2P 244134-72-3P
244134-73-4P 244134-74-5P 244134-75-6P 244134-76-7P 244134-77-8P
244134-78-9P 244134-79-0P 244134-80-3P 244134-81-4P 244134-82-5P
244134-83-6P 244134-84-7P 244134-85-8P 244134-86-9P 244134-87-0P
244134-88-1P 244134-89-2P 244134-90-5P 244134-91-6P 244134-92-7P
244134-93-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of caspases)

IT 122191-40-6, Caspase-1 169592-56-7, Caspase-3 179241-78-2, Caspase-8
182762-08-9, Caspase-4
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of peptides as inhibitors of caspases)

IT 56-41-7, L-Alanine, reactions 79-03-8, Propionyl chloride 96-41-3, Cyclopentanol 98-98-6, 2-Pyridinecarboxylic acid 100-07-2, p-Anisoyl chloride 100-49-2, Cyclohexylmethanol 103-80-0, Phenylacetyl chloride 108-12-3, Isovaleryl chloride 122-97-4, 3-Phenyl-1-propanol 400-76-0 486-73-7, 1-Isoquinolinecarboxylic acid 591-50-4, Iodobenzene 700-57-2, 2-Adamantanol 873-76-7, 4-Chlorobenzenemethanol 879-65-2, 2-Quinoxalinecarboxylic acid 944-43-4 2216-51-5 2486-71-7, 4-Amino-3-chlorobenzoic acid 3282-30-2, Pivaloyl chloride 3336-41-2 3637-61-4, Cyclopentylmethanol 4093-31-6 4254-29-9, 2-Indanol 4919-37-3, 3,5-Dimethyl-4-hydroxybenzoic acid 6223-83-2, 9-Oxo-4-fluorenecarboxylic acid 7206-70-4 10349-57-2, 6-Quinolinecarboxylic acid 15356-60-2 21553-46-8, 3,5-Dimethyl-4-methoxybenzoic acid 21803-75-8, 4-Amino-3-chlorobenzonitrile 26250-84-0 33300-72-0 37908-97-7, 3,5-Dichloro-4-methoxybenzoic acid 41727-45-1 56961-25-2, 3,5-Dichloro-4-aminobenzoic acid 58452-00-9, 3-Benzyloxy-4-methoxybenzoic acid 60108-51-2 60772-67-0, 3-Isopropoxybenzoic acid 72228-75-2 74844-91-0 103321-53-5 116939-94-7 143305-32-2 146803-45-4D, resin-bound 147650-70-2 192760-02-4 193945-93-6 220184-67-8 233266-69-8 244132-28-3D, resin-bound 244133-23-1 244133-24-2 244134-11-0 244134-14-3 244134-15-4 244134-17-6 244134-20-1 244134-21-2 244134-22-3 244134-23-4 244134-25-6 244134-26-7 244134-27-8 244134-31-4 244134-33-6 244134-36-9 244134-53-0 244134-63-2 244134-64-3
RL: RCT (Reactant)
(prepn. of peptides as inhibitors of caspases)

IT 705-61-3P 7192-39-4P 24201-13-6P, 4-Acetylamino-5-chloro-2-methoxybenzoic acid 27544-35-0P 72289-52-2P 74114-62-8P
102195-80-2P 132682-05-4P 147821-02-1P 147837-55-6P 171872-14-3P
192760-01-3P 192760-03-5P 195071-61-5P 195071-66-0P 203866-15-3P
203866-17-5P 203866-21-1P 208521-78-2P 244132-27-2P 244132-29-4P
244132-30-7P 244132-31-8P 244133-03-7P 244133-04-8P 244133-05-9P
244133-08-2P 244133-09-3P 244133-12-8P 244133-17-3P 244133-20-8P
244133-25-3P 244133-29-7P 244133-32-2P 244133-51-5P 244133-52-6P
244133-53-7P 244133-54-8P 244133-55-9P 244133-56-0P 244134-12-1P
244134-13-2P 244134-16-5P 244134-18-7P 244134-24-5P 244134-28-9P
244134-29-0P 244134-30-3P 244134-32-5P 244134-35-8P 244134-37-0P
244134-39-2P 244134-43-8P 244134-44-9P 244134-45-0P 244134-50-7P
244134-54-1P 244134-65-4P 244134-95-0P 244134-98-3P 244134-99-4P
244135-00-0P 244135-01-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides as inhibitors of caspases)

IT 97888-80-7P 244134-19-8P 244134-34-7P 244134-38-1P 244134-96-1P
244134-97-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides as inhibitors of caspases)

IT **244131-24-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of caspases)

RN 244131-24-6 HCAPLUS

CN L-Prolinamide, N-[[1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-yl]carbonyl]-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L67 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2001 ACS

AN 1998:804155 HCAPLUS

DN 130:52725

TI Preparation and use of pyrrolidines in hair growth compositions

IN Hamilton, Gregory S.; Steiner, Joseph P.

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-48

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9855090	A1	19981210	WO 1998-US11237	19980603
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945441	A	19990831	US 1997-869426	19970604
	ZA 9804621	A	19981204	ZA 1998-4621	19980529
	ZA 9804778	A	19981204	ZA 1998-4778	19980603
	ZA 9804783	A	19981204	ZA 1998-4783	19980603
	AU 9877164	A1	19981221	AU 1998-77164	19980603
	EP 983054	A1	20000308	EP 1998-925148	19980603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6239164	B1	20010529	US 1999-369860	19990809
PRAI	US 1997-869426	A	19970604		
	WO 1998-US11237	W	19980603		

GI



I



II

AB This invention relates to pharmaceutical compns. and methods for treating **alopecia** and promoting hair growth using non-immunosuppressive neuroimmunophilin FKBP ligands [I; n = 1, 2, 3; Y = CO, COCO, SO2, CS; X = O, S; Z = S, O, CH2, (CH2)3, SCH2, S(CH2)2, S(CH2)3; R1 = benzyl, 3-phenylpropyl, 3-(3-pyridyl)propyl, diphenylmethyl, etc.; R2 = cyclohexyl, Ph, tert-Bu, 3,4,5-trimethoxyphenyl, etc.], stereoisomers, pharmaceutically acceptable salts, esters, and solvates thereof. The title compd. II was tested, in vitro, in inhibition of the peptidyl-prolyl isomerase activity and preferably for use topically to the skin to treat **alopecia** or promote hair growth effectively.

ST carboxylate pyrrolidine prepn **alopecia** treatment

IT **Alopecia**
Drug delivery systems
(prepn. and use of pyrrolidines in hair growth compns.)

IT 186452-09-5P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of pyrrolidines in hair growth compns.)

IT 186268-50-8P 186268-51-9P 186268-52-0P 186268-53-1P 186268-54-2P
186268-56-4P 186268-57-5P 186268-58-6P 186268-63-3P 186268-64-4P
186268-65-5P 186268-66-6P 186268-67-7P 186268-68-8P 186452-05-1P
186452-06-2P 186452-07-3P 186452-08-4P 186452-10-8P 186452-11-9P
186452-12-0P 186452-13-1P 186452-14-2P 186452-15-3P 186452-16-4P
186452-17-5P 186452-18-6P 186452-19-7P 186452-20-0P 205388-13-2P
205388-14-3P 205388-15-4P 205388-16-5P 205388-18-7P 205388-19-8P
205388-20-1P 205388-21-2P 205388-22-3P 205388-23-4P 205388-24-5P
205388-25-6P 205388-26-7P 205388-27-8P 205388-28-9P 205388-29-0P
205388-30-3P 205388-31-4P 205388-32-5P 205388-33-6P 205388-34-7P
205388-35-8P 205388-36-9P 205388-37-0P 205388-38-1P 205388-39-2P
205388-41-6P 205388-42-7P 205388-43-8P 205388-44-9P 205388-47-2P
205388-48-3P 205388-49-4P 205388-50-7P 205388-53-0P 205388-54-1P
205388-55-2P 205388-56-3P 205388-57-4P 205388-58-5P 205388-59-6P
205388-61-0P 205388-62-1P 205388-63-2P 205388-80-3P
205448-79-9P **205448-80-2P** 210048-08-1P 210048-10-5P
210048-11-6P 210048-12-7P 210048-13-8P 210048-14-9P 210048-15-0P
210048-16-1P 210048-17-2P 210048-18-3P 210048-19-4P 210048-20-7P
210048-21-8P 210048-22-9P 210048-23-0P 210048-25-2P 210103-54-1P
210103-55-2P 210103-60-9P 212762-79-3P 217178-10-4P 217179-46-9P
217179-50-5P 217180-44-4P 217180-57-9P 217180-59-1P 217180-90-0P
217186-43-1P 217186-45-3P 217186-46-4P 217186-47-5P 217186-49-7P

217186-50-0P 217186-51-1P 217186-52-2P 217186-53-3P 217186-54-4P
217186-55-5P 217186-56-6P 217186-57-7P 217186-58-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of pyrrolidines in hair growth compns.)

IT 86-81-7, 3,4,5-Trimethoxybenzaldehyde 96-15-1, 2-Methylbutylamine 103-63-9, 2-(Bromoethyl)benzene 108-98-5, Phenyl mercaptan, reactions 122-97-4, 3-Phenyl-1-propanol 558-13-4, Carbontetrabromide 955-40-8 1122-82-3, Cyclohexylisothiocyanate 2577-48-2, L-Proline methyl ester 2859-67-8, 3-Pyridinepropanol 4830-93-7, 1-Chloro-4-phenylbutane 5406-18-8, 3-(p-Methoxyphenyl)-1-propanol 5781-53-3, Methyloxalyl chloride 20329-96-8, Methyl (E)-3,4,5-Trimethoxycinnamate 26250-84-0 28276-08-6, 1,1-Dimethylpropylmagnesium chloride 32559-18-5, Methyl pipecolate hydrochloride 34592-47-7 53560-26-2
RL: RCT (Reactant)
(prepn. and use of pyrrolidines in hair growth compns.)

IT 104-53-0P, 3-Phenyl-1-propanal 17486-86-1P, 1,5-Diphenyl-3-pentanol 21011-66-5P 57293-19-3P 69603-49-2P, 3-Pyridinepropanethiol 88537-44-4P 89113-44-0P 139419-63-9P 186268-77-9P 186268-78-0P 205388-66-5P 205388-67-6P 205388-68-7P 205448-82-4P 210048-37-6P 210048-38-7P 210103-98-3P 210103-99-4P 217186-09-9P 217186-59-9P 217186-60-2P 217186-61-3P 217186-62-4P 217186-63-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and use of pyrrolidines in hair growth compns.)

RE.CNT 3
RE
(1) Ariad Gene Therapeutics, Inc; WO 9731898 A 1997 HCAPLUS
(2) Hamilton, G; US 5614547 A 1997 HCAPLUS
(3) The Board of Trustees of the Leland Stanford Junior Univ; WO 9502684 A 1995 HCAPLUS

IT **205448-79-9P 205448-80-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of pyrrolidines in hair growth compns.)

RN 205448-79-9 HCAPLUS
CN 4-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-phenylpropyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



claim 28

RN 205448-80-2 HCAPLUS
CN 4-Thiazolidinecarboxylic acid, 3-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Claim 28